The Role of Neoadjuvant Versus Adjuvant Therapy for Duodenal Adenocarcinoma: A National Cancer Database Propensity Score Matched Analysis. Issue 7 (July 2021)

• Record Type: Journal Article
• Authors: Linden, Kimberly; Melillo, Atlee; Gaughan, John; Obinero, Chioma; Kellish, Alec; Wozniak, Marisa R.; Patel, Raj M.; Pandya, Vidish; Atabek, Umur; Spitz, Francis; Hong, Young K.
• Is Part Of: American surgeon. Volume 87:Issue 7(2021)
• Page Start: 1066
• Page End: 1073
• Publication Date: 2021-07
• Subjects: duodenal adenocarcinoma -- neoadjuvant therapy -- adjuvant therapy; Surgery -- Periodicals; Surgery -- United States -- Periodicals; 617.0973
• DOI: 10.1177/0003134820954821
• Languages: English
• ISSNs: 0003-1348

Abstract

Introduction: Adjuvant therapy is recommended in duodenal adenocarcinoma (DA), but the role of neoadjuvant therapy remains undefined. We compared the effect of neoadjuvant therapy to adjuvant therapy on overall survival, 30-day, and 90-day mortality following the resection of DA. Methods: A retrospective review of the National Cancer Database was performed on patients with DA who received either adjuvant or neoadjuvant therapy in addition to surgical resection. Propensity score matching was done for patient, socioeconomic, and tumor characteristics. Overall survival, 30-day, and 90-day mortality were compared. Results: A total of 112 patients were identified; 55 received adjuvant therapy; 57 received neoadjuvant therapy. There was no difference in 30-day (0% vs. 1.75%; P = 1.00), 90-day mortality (1.82% vs. 7.02%; P = .36), nor overall survival (1 yr: 86% vs. 76; 3 yr: 49% vs. 46%; 5 yr: 42% vs. 39%; P = .28). Conclusions: There was no difference in overall survival after propensity score matched analysis.